;PMID: 1554389
;source_file_2658.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..179] = [t:49..179]
;2)sentence:[e:180..207] = [t:180..207]
;3)section:[e:211..223] = [t:211..223]
;4)section:[e:227..301] = [t:227..301]
;5)sentence:[e:305..420] = [t:305..420]
;6)sentence:[e:421..537] = [t:421..537]
;7)sentence:[e:538..705] = [t:538..705]
;8)sentence:[e:706..877] = [t:706..877]
;9)sentence:[e:878..938] = [t:878..938]
;10)sentence:[e:939..1053] = [t:939..1053]
;11)sentence:[e:1054..1179] = [t:1054..1179]
;12)sentence:[e:1180..1356] = [t:1180..1356]
;13)sentence:[e:1357..1491] = [t:1357..1491]
;14)sentence:[e:1492..1584] = [t:1492..1584]
;15)sentence:[e:1585..1707] = [t:1585..1707]
;16)section:[e:1711..1755] = [t:1711..1755]

;section 0 Span:0..43
;Biochem Pharmacol. 1992 Mar 3;43(5):1163-6.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (.:[17..18] .)
        (CD:[19..23] 1992) (NNP:[24..27] Mar) (CD:[28..32] 3;43)
        (-LRB-:[32..33] -LRB-) (CD:[33..34] 5) (-RRB-:[34..35] -RRB-)
        (::[35..36] :) (CD:[36..40] 1163) (HYPH:[40..41] -) (CD:[41..43] 6.)))

;sentence 1 Span:49..179
;Interleukin-1, platelet derived growth factor, free radicals and monocyte
;aryl  hydrocarbon hydroxylase activity in liver disease.
;[49..62]:substance:"Interleukin-1"
;[64..94]:substance:"platelet derived growth factor"
;[101..109]:substance:"radicals"
;[123..152]:cyp450:"aryl  hydrocarbon hydroxylase"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[49..62] Interleukin-1))
      (,:[62..63] ,)
      (NP
        (ADJP (NN:[64..72] platelet) (VBN:[73..80] derived))
        (NN:[81..87] growth) (NN:[88..94] factor))
      (,:[94..95] ,)
      (NP (JJ:[96..100] free) (NNS:[101..109] radicals))
      (CC:[110..113] and)
      (NP (NN:[114..122] monocyte)
        
        (NML (NN:[123..127] aryl) (NN:[129..140] hydrocarbon))
        (NN:[141..152] hydroxylase)
        (NN:[153..161] activity)))
    (PP (IN:[162..164] in)
      (NP (NN:[165..170] liver) (NN:[171..178] disease)))
    (.:[178..179] .)))

;sentence 2 Span:180..207
;Role of cell communication.
(SENT
  (NP-HLN
    (NP (NN:[180..184] Role))
    (PP (IN:[185..187] of)
      (NP (NN:[188..192] cell) (NN:[193..206] communication)))
    (.:[206..207] .)))

;section 3 Span:211..223
;Peterson TC.
(SEC
  (FRAG (NNP:[211..219] Peterson) (NNP:[220..222] TC) (.:[222..223] .)))

;section 4 Span:227..301
;Department of Medicine, Dalhousie University Halifax, Nova Scotia, Canada.
(SEC
  (FRAG (NNP:[227..237] Department) (IN:[238..240] of) (NNP:[241..249] Medicine)
        (,:[249..250] ,) (NNP:[251..260] Dalhousie) (NNP:[261..271] University)
        (NNP:[272..279] Halifax) (,:[279..280] ,) (NNP:[281..285] Nova)
        (NNP:[286..292] Scotia) (,:[292..293] ,) (NNP:[294..300] Canada)
        (.:[300..301] .)))

;sentence 5 Span:305..420
;Monocytes were isolated from blood of human origin and cultured in
;supplemented  Leibovitz (L-15) medium for 24 hr.
;[386..409]:substance:"Leibovitz (L-15) medium"
;[414..416]:quantitative-value:"24"
;[417..419]:quantitative-units:"hr"
(SENT
  (S (NNS:[305..314] Monocytes)
    (VP (VBD:[315..319] were)
      (VP
        (VP (VBN:[320..328] isolated)
          (NP-1 (-NONE-:[328..328] *))
          (PP (IN:[329..333] from)
            (NP
              (NP (NN:[334..339] blood))
              (PP (IN:[340..342] of)
                (NP (JJ:[343..348] human) (NN:[349..355] origin))))))
        (CC:[356..359] and)
        (VP (VBN:[360..368] cultured)
          (NP-1 (-NONE-:[368..368] *))
          (PP-LOC (IN:[369..371] in)
            (NP (VBN:[372..384] supplemented)
              
              (NML
                (NML (NNP:[386..395] Leibovitz))
                (NML (-LRB-:[396..397] -LRB-) (NN:[397..401] L-15)
                     (-RRB-:[401..402] -RRB-)))
              (NN:[403..409] medium)))
          (PP-TMP (IN:[410..413] for)
            (NP (CD:[414..416] 24) (NN:[417..419] hr))))))
    (.:[419..420] .)))

;sentence 6 Span:421..537
;The medium was then decanted and filtered,  and all subsequent tests were
;done on monocyte conditioned medium (MCM).
;[425..431]:substance:"medium"
;[503..530]:substance:"monocyte conditioned medium"
;[532..535]:substance:"MCM"
(SENT
  (S
    (S
      (NP-SBJ-1 (DT:[421..424] The) (NN:[425..431] medium))
      (VP (VBD:[432..435] was)
        (ADVP-TMP (RB:[436..440] then))
        (VP (VBN:[441..449] decanted) (CC:[450..453] and)
            (VBN:[454..462] filtered)
          (NP-1 (-NONE-:[462..462] *)))))
    (,:[462..463] ,) (CC:[465..468] and)
    (S
      (NP-SBJ-2 (DT:[469..472] all) (JJ:[473..483] subsequent)
                (NNS:[484..489] tests))
      (VP (VBD:[490..494] were)
        (VP (VBN:[495..499] done)
          (NP-2 (-NONE-:[499..499] *))
          (PP-CLR (IN:[500..502] on)
            (NP
              (NP
                (ADJP (NN:[503..511] monocyte) (VBN:[512..523] conditioned))
                (NN:[524..530] medium))
              (NP (-LRB-:[531..532] -LRB-) (NN:[532..535] MCM)
                  (-RRB-:[535..536] -RRB-)))))))
    (.:[536..537] .)))

;sentence 7 Span:538..705
;The  monocytes of patients with liver disease spontaneously secrete 
;temperature-sensitive arylhydrocarbon hydroxylase (AHH) inhibitory factors 
;detectable in the MCM.
;[629..681]:substance:"arylhydrocarbon hydroxylase (AHH) inhibitory factors"
;[701..704]:substance:"MCM"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[538..541] The) (NNS:[543..552] monocytes))
      (PP (IN:[553..555] of)
        (NP
          (NP (NNS:[556..564] patients))
          (PP (IN:[565..569] with)
            (NP (NN:[570..575] liver) (NN:[576..583] disease))))))
    (ADVP-MNR (RB:[584..597] spontaneously))
    (VP (VBP:[598..605] secrete)
      (NP
        (NP
          (ADJP (NN:[607..618] temperature) (HYPH:[618..619] -)
                (JJ:[619..628] sensitive))
          
          (ADJP
            (NML
              (NML (NN:[629..644] arylhydrocarbon) (NN:[645..656] hydroxylase))
              (NML (-LRB-:[657..658] -LRB-) (NN:[658..661] AHH)
                   (-RRB-:[661..662] -RRB-)))
            (JJ:[663..673] inhibitory))
          (NNS:[674..681] factors))
        (ADJP (JJ:[683..693] detectable)
          (PP-LOC (IN:[694..696] in)
            (NP (DT:[697..700] the) (NN:[701..704] MCM))))))
    (.:[704..705] .)))

;sentence 8 Span:706..877
;Anti-interleukin-1 antibody (IL-1Ab) reduced the AHH  inhibitory activity of
;the MCM, suggesting that part of the AHH inhibitory  activity was due to
;interleukin-1 (IL-1).
;[706..733]:substance:"Anti-interleukin-1 antibody"
;[735..741]:substance:"IL-1Ab"
;[755..758]:cyp450:"AHH"
;[787..790]:substance:"MCM"
;[820..823]:cyp450:"AHH"
;[856..869]:substance:"interleukin-1"
;[871..875]:substance:"IL-1"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (AFX:[706..710] Anti) (HYPH:[710..711] -)
             (NN:[711..724] interleukin-1))
        (NN:[725..733] antibody))
      (NP (-LRB-:[734..735] -LRB-) (NN:[735..741] IL-1Ab)
          (-RRB-:[741..742] -RRB-)))
    (VP (VBD:[743..750] reduced)
      (NP
        (NP (DT:[751..754] the)
          (ADJP (NN:[755..758] AHH) (JJ:[760..770] inhibitory))
          (NN:[771..779] activity))
        (PP (IN:[780..782] of)
          (NP (DT:[783..786] the) (NN:[787..790] MCM))))
      (,:[790..791] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[791..791] *))
        (VP (VBG:[792..802] suggesting)
          (SBAR (IN:[803..807] that)
            (S
              (NP-SBJ
                (NP (NN:[808..812] part))
                (PP (IN:[813..815] of)
                  (NP (DT:[816..819] the)
                    (ADJP (NN:[820..823] AHH) (JJ:[824..834] inhibitory))
                    (NN:[836..844] activity))))
              (VP (VBD:[845..848] was)
                (PP-PRD (IN:[849..852] due)
                  (PP (TO:[853..855] to)
                    (NP
                      (NP (NN:[856..869] interleukin-1))
                      (NP (-LRB-:[870..871] -LRB-) (NN:[871..875] IL-1)
                          (-RRB-:[875..876] -RRB-)))))))))))
    (.:[876..877] .)))

;sentence 9 Span:878..938
;Platelet derived growth factor did not  affect AHH activity.
;[878..908]:substance:"Platelet derived growth factor"
;[925..928]:cyp450:"AHH"
(SENT
  (S
    (NP-SBJ
      (ADJP (NN:[878..886] Platelet) (VBN:[887..894] derived))
      (NN:[895..901] growth) (NN:[902..908] factor))
    (VP (VBD:[909..912] did) (RB:[913..916] not)
      (VP (VB:[918..924] affect)
        (NP (NN:[925..928] AHH) (NN:[929..937] activity))))
    (.:[937..938] .)))

;sentence 10 Span:939..1053
;Interleukin-1 beta was detectable in MCM but did not differ  significantly
;between patients and normal volunteers.
;[939..957]:substance:"Interleukin-1 beta"
;[976..979]:substance:"MCM"
(SENT
  (S
    (NP-SBJ (NN:[939..952] Interleukin-1) (SYM:[953..957] beta))
    (VP
      (VP (VBD:[958..961] was)
        (ADJP-PRD (JJ:[962..972] detectable))
        (PP-LOC (IN:[973..975] in)
          (NP (NN:[976..979] MCM))))
      (CC:[980..983] but)
      (VP (VBD:[984..987] did) (RB:[988..991] not)
        (VP (VB:[992..998] differ)
          (ADVP-MNR (RB:[1000..1013] significantly))
          (PP (IN:[1014..1021] between)
            (NP
              (NP (NNS:[1022..1030] patients))
              (CC:[1031..1034] and)
              (NP (JJ:[1035..1041] normal) (NNS:[1042..1052] volunteers)))))))
    (.:[1052..1053] .)))

;sentence 11 Span:1054..1179
;A time course experiment  indicated that interleukin-1 beta inhibited
;hepatocyte AHH activity after only 2  hr of incubation.
;[1095..1113]:substance:"interleukin-1 beta"
;[1135..1138]:cyp450:"AHH"
;[1159..1160]:quantitative-value:"2"
;[1162..1164]:quantitative-units:"hr"
(SENT
  (S
    (NP-SBJ (DT:[1054..1055] A)
      (NML (NN:[1056..1060] time) (NN:[1061..1067] course))
      (NN:[1068..1078] experiment))
    (VP (VBD:[1080..1089] indicated)
      (SBAR (IN:[1090..1094] that)
        (S
          (NP-SBJ (NN:[1095..1108] interleukin-1) (SYM:[1109..1113] beta))
          (VP (VBD:[1114..1123] inhibited)
            (NP (NN:[1124..1134] hepatocyte) (NN:[1135..1138] AHH)
                (NN:[1139..1147] activity))
            (PP-TMP (IN:[1148..1153] after)
              (NP
                (NP
                  (QP (RB:[1154..1158] only) (CD:[1159..1160] 2))
                  (NN:[1162..1164] hr))
                (PP (IN:[1165..1167] of)
                  (NP (NN:[1168..1178] incubation)))))))))
    (.:[1178..1179] .)))

;sentence 12 Span:1180..1356
;Catalase partially blocked the AHH inhibitory activity of MCM  suggesting
;that activated oxygen intermediates are partially involved in the AHH 
;inhibitory activity of the MCM.
;[1180..1188]:substance:"Catalase"
;[1211..1214]:cyp450:"AHH"
;[1238..1241]:substance:"MCM"
;[1269..1289]:substance:"oxygen intermediates"
;[1320..1323]:cyp450:"AHH"
;[1352..1355]:substance:"MCM"
(SENT
  (S
    (NP-SBJ (NN:[1180..1188] Catalase))
    (ADVP-EXT (RB:[1189..1198] partially))
    (VP (VBD:[1199..1206] blocked)
      (NP
        (NP (DT:[1207..1210] the)
          (NML (NN:[1211..1214] AHH) (JJ:[1215..1225] inhibitory))
          (NN:[1226..1234] activity))
        (PP (IN:[1235..1237] of)
          (NP (NN:[1238..1241] MCM))))
      (S-MNR
        (NP-SBJ (-NONE-:[1241..1241] *))
        (VP (VBG:[1243..1253] suggesting)
          (SBAR (IN:[1254..1258] that)
            (S
              (NP-SBJ-1 (VBN:[1259..1268] activated)
                 (NN:[1269..1275] oxygen) (NNS:[1276..1289] intermediates))
              (VP (VBP:[1290..1293] are)
                (ADVP-EXT (RB:[1294..1303] partially))
                (VP (VBN:[1304..1312] involved)
                  (NP-1 (-NONE-:[1312..1312] *))
                  (PP-CLR (IN:[1313..1315] in)
                    (NP
                      (NP (DT:[1316..1319] the)
                        (NML (NN:[1320..1323] AHH) (JJ:[1325..1335] inhibitory))
                        (NN:[1336..1344] activity))
                      (PP (IN:[1345..1347] of)
                        (NP (DT:[1348..1351] the) (NN:[1352..1355] MCM))))))))))))
    (.:[1355..1356] .)))

;sentence 13 Span:1357..1491
;Simultaneous incubation of interleukin-1 beta  and catalase did not prevent
;or augment the inhibitory action of IL-1 on AHH  activity.
;[1384..1402]:substance:"interleukin-1 beta"
;[1408..1416]:substance:"catalase"
;[1469..1473]:substance:"IL-1"
;[1477..1480]:cyp450:"AHH"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1357..1369] Simultaneous) (NN:[1370..1380] incubation))
      (PP (IN:[1381..1383] of)
        (NP
          (NP (NN:[1384..1397] interleukin-1) (SYM:[1398..1402] beta))
          (CC:[1404..1407] and)
          (NP (NN:[1408..1416] catalase)))))
    (VP (VBD:[1417..1420] did) (RB:[1421..1424] not))
    (VP (VB:[1425..1432] prevent) (CC:[1433..1435] or) (VB:[1436..1443] augment)
      (NP
        (NP (DT:[1444..1447] the) (JJ:[1448..1458] inhibitory)
            (NN:[1459..1465] action))
        (NP (IN:[1466..1468] of)
          (NP (NN:[1469..1473] IL-1)))
        (PP (IN:[1474..1476] on)
          (NP (NN:[1477..1480] AHH) (NN:[1482..1490] activity)))))
    (.:[1490..1491] .)))

;sentence 14 Span:1492..1584
;IL-1 stimulates collagen synthesis and elevates serum procollagen type  3
;peptide (P-III-P).
;[1492..1496]:substance:"IL-1"
;[1508..1516]:substance:"collagen"
;[1546..1573]:substance:"procollagen type  3 peptide"
;[1575..1582]:substance:"P-III-P"
(SENT
  (S
    (NP-SBJ (NN:[1492..1496] IL-1))
    (VP
      (VP (VBZ:[1497..1507] stimulates)
        (NP (NN:[1508..1516] collagen) (NN:[1517..1526] synthesis)))
      (CC:[1527..1530] and)
      (VP (VBZ:[1531..1539] elevates)
        (NP
          (NP (NN:[1540..1545] serum)
             (NN:[1546..1557] procollagen)
            (NML (NN:[1558..1562] type) (CD:[1564..1565] 3))
            (NN:[1566..1573] peptide))
          (NP (-LRB-:[1574..1575] -LRB-) (NN:[1575..1582] P-III-P)
              (-RRB-:[1582..1583] -RRB-)))))
    (.:[1583..1584] .)))

;sentence 15 Span:1585..1707
;Results indicated that serum P-III-P was elevated in blood  sources producing
;temperature-sensitive AHH inhibitory factor.
;[1614..1621]:substance:"P-III-P"
;[1685..1706]:substance:"AHH inhibitory factor"
(SENT
  (S
    (NP-SBJ (NNS:[1585..1592] Results))
    (VP (VBD:[1593..1602] indicated)
      (SBAR (IN:[1603..1607] that)
        (S
          (NP-SBJ-1 (NN:[1608..1613] serum) (NN:[1614..1621] P-III-P))
          (VP (VBD:[1622..1625] was)
            (VP (VBN:[1626..1634] elevated)
              (NP-1 (-NONE-:[1634..1634] *))
              (PP-LOC (IN:[1635..1637] in)
                (NP
                  (NP (NN:[1638..1643] blood) (NNS:[1645..1652] sources))
                  (VP (VBG:[1653..1662] producing)
                    (NP
                      (ADJP (NN:[1663..1674] temperature) (HYPH:[1674..1675] -)
                            (JJ:[1675..1684] sensitive))
                      
                      (ADJP (NN:[1685..1688] AHH) (JJ:[1689..1699] inhibitory))
                      (NN:[1700..1706] factor))))))))))
    (.:[1706..1707] .)))

;section 16 Span:1711..1755
;PMID: 1554389 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1711..1715] PMID) (::[1715..1716] :) (CD:[1717..1724] 1554389)
        (NN:[1725..1726] -LSB-) (NNP:[1726..1732] PubMed) (::[1733..1734] -)
        (NN:[1735..1742] indexed) (IN:[1743..1746] for)
        (NNP:[1747..1755] MEDLINE-RSB-)))
